<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Penthala NR</submitter><funding>NCI/NIH</funding><funding>NCI Developmental Therapeutic Program (DTP)</funding><funding>NCI NIH HHS</funding><funding>Arkansas Research Alliance (ARA)</funding><pagination>1442-6</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4167626</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(5)</volume><pubmed_abstract>A series of novel 5-((1-aroyl-1H-indol-3-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-diones (3a-z) have been evaluated for in vitro cytotoxicity against a panel of 60 human tumor cell lines. Compound 3k exhibited the most potent growth inhibition against melanoma MDA-MB-435 cells (GI(50)=850 nM), against leukemia SR cancer cells (GI(50)=1.45 μM), and OVCAR-3 (GI(50)=1.26 μM) ovarian cancer cell lines. The structurally related compound 3s had a GI(50) value of 1.77 μM against MDA-MB-435 cells. The N-naphthoyl analogue 3t had GI(50) values of 1.30 and 1.91 μM against HOP-92 non-small cell lung cancer and MDA-MB-435 melanoma cell lines, respectively. The related analogue 3w had GI(50) values of 1.09 μM against HOP-92 non-small cell lung cancer cell lines. Interestingly, docking of the </pubmed_abstract><journal>Bioorganic &amp; medicinal chemistry letters</journal><pubmed_title>5-((1-Aroyl-1H-indol-3-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-diones as potential anticancer agents with anti-inflammatory properties.</pubmed_title><pmcid>PMC4167626</pmcid><funding_grant_id>R01 CA140409</funding_grant_id><funding_grant_id>CA 140409</funding_grant_id><pubmed_authors>Ponugoti PR</pubmed_authors><pubmed_authors>Kasam V</pubmed_authors><pubmed_authors>Penthala NR</pubmed_authors><pubmed_authors>Crooks PA</pubmed_authors></additional><is_claimable>false</is_claimable><name>5-((1-Aroyl-1H-indol-3-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-diones as potential anticancer agents with anti-inflammatory properties.</name><description>A series of novel 5-((1-aroyl-1H-indol-3-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-diones (3a-z) have been evaluated for in vitro cytotoxicity against a panel of 60 human tumor cell lines. Compound 3k exhibited the most potent growth inhibition against melanoma MDA-MB-435 cells (GI(50)=850 nM), against leukemia SR cancer cells (GI(50)=1.45 μM), and OVCAR-3 (GI(50)=1.26 μM) ovarian cancer cell lines. The structurally related compound 3s had a GI(50) value of 1.77 μM against MDA-MB-435 cells. The N-naphthoyl analogue 3t had GI(50) values of 1.30 and 1.91 μM against HOP-92 non-small cell lung cancer and MDA-MB-435 melanoma cell lines, respectively. The related analogue 3w had GI(50) values of 1.09 μM against HOP-92 non-small cell lung cancer cell lines. Interestingly, docking of the </description><dates><release>2013-01-01T00:00:00Z</release><publication>2013 Mar</publication><modification>2025-04-03T22:43:21.233Z</modification><creation>2019-03-27T01:35:52Z</creation></dates><accession>S-EPMC4167626</accession><cross_references><pubmed>23339966</pubmed><doi>10.1016/j.bmcl.2012.12.053</doi></cross_references></HashMap>